173 related articles for article (PubMed ID: 19332765)
1. How I treat symptomatic splenomegaly in patients with myelofibrosis.
Mesa RA
Blood; 2009 May; 113(22):5394-400. PubMed ID: 19332765
[TBL] [Abstract][Full Text] [Related]
2. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
4. Modern management of splenomegaly in patients with myelofibrosis.
Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J
Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942
[TBL] [Abstract][Full Text] [Related]
5. Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020?
Sankar K; Pettit K
Curr Hematol Malig Rep; 2020 Oct; 15(5):391-400. PubMed ID: 32827272
[TBL] [Abstract][Full Text] [Related]
6. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
8. Assessing new therapies and their overall impact in myelofibrosis.
Mesa RA
Hematology Am Soc Hematol Educ Program; 2010; 2010():115-21. PubMed ID: 21239780
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
10. How I treat myelofibrosis.
Cervantes F
Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
[TBL] [Abstract][Full Text] [Related]
11. How I treat splenomegaly in myelofibrosis.
Cervantes F
Blood Cancer J; 2011 Oct; 1(10):e37. PubMed ID: 22829071
[TBL] [Abstract][Full Text] [Related]
12. Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications.
Malato A; Rossi E; Tiribelli M; Mendicino F; Pugliese N
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):588-595. PubMed ID: 32482540
[TBL] [Abstract][Full Text] [Related]
13. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
Ishibashi N; Maebayashi T; Aizawa T; Sakaguchi M; Abe O; Saito T; Tanaka Y
Hematology; 2015 May; 20(4):203-7. PubMed ID: 25131182
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
15. Management of myelofibrosis.
Vannucchi AM
Hematology Am Soc Hematol Educ Program; 2011; 2011():222-30. PubMed ID: 22160038
[TBL] [Abstract][Full Text] [Related]
16. [Role of splenectomy in the treatment of myelofibrosis].
Melikian AL; Kolosova LIu; Sokolova MA; Kovrigina AM; Silaev MA; Giliazitdinova EA; Gemdzhian ÉG; Karagiulian SR
Ter Arkh; 2013; 85(8):69-76. PubMed ID: 24137967
[TBL] [Abstract][Full Text] [Related]
17. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy.
Pardanani A; Brown P; Neben-Wittich M; Tobin R; Tefferi A
Am J Hematol; 2010 Sep; 85(9):715-6. PubMed ID: 20661915
[TBL] [Abstract][Full Text] [Related]
18. Treatment and management of myelofibrosis in the era of JAK inhibitors.
Keohane C; Radia DH; Harrison CN
Biologics; 2013; 7():189-98. PubMed ID: 23990704
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal carcinomatosis-like implants of extramedullary hematopoiesis. An insolite occurrence during splenectomy for myelofibrosis.
Casaccia M; Fornaro R; Frascio M; Palombo D; Stabilini C; Firpo E; Gianetta E
Int J Surg Case Rep; 2017; 41():9-11. PubMed ID: 29024842
[TBL] [Abstract][Full Text] [Related]
20. Transplant strategies for idiopathic myelofibrosis.
McCarty JM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):23-9. PubMed ID: 15190520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
